NINA Capital Buys 25,000 PETMED Shares Amid Insider Buying Surge—Is a Comeback on the Horizon?

NINA CAPITAL HOLDINGS INC. has just purchased 25,000 shares of PETMED EXPRESS INC. Common Stock at $1.75 per share, bringing the holding to 2.6 million shares. The acquisition came on a backdrop of a steep decline in the company’s market value—down 54 % year‑to‑date and a 19 % drop last week—yet the price paid is only marginally above the current $1.71 market price. For a firm that has seen its share price fall from nearly $19 in 2016 to about $1.70 today, the purchase signals a calculated bet on a rebound or at least a stabilization of its retail‑pharmacy model.

The transaction sits alongside a cluster of insider activity that hints at mixed sentiment among PETMED’s leadership. In the first quarter of 2026, CFO‑interim Douglas Krulik bought 20,000 shares, while other executives made sizeable purchases in October 2025, collectively adding roughly 180,000 shares to their holdings. Conversely, a January 2026 sale by Gian Fulgoni off‑loaded 26,057 shares. This blend of buying and selling is typical for a company in transition, suggesting that insiders are hedging their positions while still maintaining long‑term confidence in the business. The recent purchase by NINA Capital, a professional investment firm, can be viewed as a reinforcing signal that external capital is willing to commit to the company’s long‑term growth prospects.

From an investor perspective, the implications are twofold. First, the modest premium paid by NINA Capital—only 0.1 % above the market price—indicates that the firm is not overpaying for a distressed asset, which may mitigate concerns about overvaluation. Second, the sustained insider buying, despite a weak market price, points to a belief that the company’s consumer‑pet‑care niche can recover once the competitive pressures subside. Should PETMED successfully capitalize on its online pharmacy footprint and expand into new product lines, the stock could find a new upward trajectory. However, the company’s negative price‑earnings ratio and declining market cap warn that any turnaround will need to be backed by tangible earnings improvement and a clear path to profitability.

In sum, the latest insider transaction by NINA Capital is a cautiously optimistic move that dovetails with the broader pattern of insider buying. While the stock remains undervalued by traditional metrics, the concentration of professional and executive ownership may help drive strategic initiatives. Investors monitoring PETMED EXPRESS should watch for earnings guidance, inventory turnover, and any signs of renewed customer acquisition as key indicators that could validate the current ownership confidence.